RNF144A as a potential risk gene for endometrial carcinoma: Insights from Mendelian randomization, bulk RNA sequencing, single-cell RNA, and experimental analysis

Xiqin Ruan,Ni Wang,Qingwen Xie,Yi Du

DOI: https://doi.org/10.1097/md.0000000000039886

IF: 1.6

2024-10-09

Medicine

Abstract:Endometrial carcinoma (EC) is the most common gynecological cancer in developed countries, with a rise of 55% in incidence and 23% in mortality over the past 30 years. [ 1 ] EC is clinically categorized into 2 main subtypes: type I, including endometrioid adenocarcinomas and mucinous adenocarcinomas, and type II, characterized by less common pathological variants like clear cell carcinoma, serous carcinoma, and carcinosarcoma. [ 2 ] The endometrioid adenocarcinoma subtype is the most prevalent form of EC. Thanks to its generally slow growth and early symptom detection, including abnormal vaginal bleeding, the majority of EC cases are discovered at an early stage. [ 3 , 4 ] Early detection allows for treatment with surgery, potentially combined with radiation or chemotherapy, which can lead to a 5-year survival rate ranging from 74% to 91%. [ 5 ] Conversely, patients with poorly differentiated tumors or those with metastasis face a markedly lower 5-year survival rate. [ 6 ] Despite these treatment modalities, effective biomarkers for the prognostic evaluation and routine diagnosis of EC remain elusive. In the last 10 years, the advent of immunotherapy, particularly immune checkpoint inhibitors, has marked a significant shift in the treatment of various solid tumors, including advanced or recurrent EC, melanoma, and several others. [ 7–9 ] Nonetheless, the effectiveness of immune checkpoint inhibitors is often constrained by factors such as the status of DNA mismatch repair. [ 10 ] Consequently, there is a necessity to uncover more effective biomarkers, providing a theoretical basis for the construction of accurate prognostic feature models to predict patient outcomes.

medicine, general & internal